[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369374-105":59,"doc-detail-369374-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-dkk3-to-remodel-tumor-immune-microenvironment-and-enhance-cancer-immunotherapy","Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy","","Cancer immunotherapy, including immune checkpoint blockade (ICB), improves outcomes but only benefits a subset of patients. The suppressive tumor immune microenvironment (TIME) limits immunotherapy response, creating a need for new targets. This study identifies Dickkopf-3 (DKK3) as a promising immunotherapeutic target: DKK3 is up-regulated in tumors across cancer types and correlates with worse survival. DKK3 suppresses CD8+ T cell activation and Th1 differentiation, while blockade remodels TIME and synergizes with PD-1 inhibition in mouse models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-dkk3-to-remodel-tumor-immune-microenvironment-and-enhance-cancer-immunotherapy/369374/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-dkk3-to-remodel-tumor-immune-microenvironment-and-enhance-cancer-immunotherapy/369374.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a new cancer immunotherapy target needed beyond immune checkpoint blockade?","Question",{"text":112,"@type":113},"Only a limited subgroup of patients responds to ICB therapy. The suppressive tumor immune microenvironment (TIME) hampers anti-tumor immune responses, necessitating new targets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the study report about DKK3 expression and patient outcomes?",{"text":117,"@type":113},"DKK3 expression is up-regulated in tumors from multiple cancer types. High DKK3 expression is associated with worse survival outcomes across different cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How does DKK3 blockade affect anti-tumor immunity and therapy response?",{"text":121,"@type":113},"DKK3 blockade triggers effective anti-tumor effects in mouse models and improves survival. It remodels TIME by increasing infiltration of CD8+ T cells, IFN-γ+CD8+ T cells, and Th1 cells while decreasing M2 macrophages and MDSCs. Combined DKK3 and PD-1 blockade shows synergistic tumor control.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369374,1790240448,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Shi et al. BMC Cancer (2025) 25:645  \n[https://doi.org/10.1186/s12885-025-14075-2](https://doi.org/10.1186/s12885-025-14075-2)  \nBMC Cancer  \nRESEARCH Open Access  \nTargeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy  \nKai Shi 1, Yan Zhao 1, Hao Ye 1, Xiaoming Zhu 1 and Zhenghai Chen 1*  \nAbstract  \nCancer immunotherapy such as immune checkpoint blockade (ICB) therapy has made important breakthroughs in cancer treatment, however, currently only parts of cancer patients benefit from ICB therapy. The suppressive tumor immune microenvironment (TIME) impedes the treatment response of immunotherapy, indicating the necessity to explore new treatment targets. Here, we reported a new potential immunotherapeutic target, Dickkopf-3 (DKK3), for cancer treatment. DKK3 expression is up-regulated in the tumors from multiple cancer types, and high DKK3 expression is associated with worse survival outcome across different cancers. We observed that DKK3 directly inhibits the activation of CD8+ T cells and the Th1 differentiation of CD4+ T cell s ex vivo. Also, by establishing four different mouse cancer models, we found that DKK3 blockade triggers effective anti-tumor effects and improve the survival of tumor-bearing mice in vivo. DKK3 blockade also remodels the suppressive TIME of different cancer types, including the increased infiltration of CD8+ T cells, IFN-γ+CD8+ T cells, Th1 cells, and decreased infiltration of M2 macrophages and MDSCs in the TIME. Moreover, we found that combined blockade of DKK3 and PD-1 induces synergistic tumor-control effect in our mouse cancer model. Therefore, our study reveals the impact of DKK3 in the TIME and cancer progression, which suggests that DKK3 is a novel and promising immunotherapeutic target for enhanced cancer immunotherapy.  \nKeywords DKK3, Tumor immune microenvironment, T cell, PD-1 Blockade, Cancer immunotherapy  \nIntroduction  \nCancer immunotherapy has brought revolutionary treatment breakthroughs of various malignancies by fueling the human immune system to recognize and destroy tumor cells [1, 2]. There have been notable successes in the clinical application of immune checkpoint inhibitors (ICIs), in particular those targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated  \n*Correspondence: Zhenghai Chen[czh42778@163.com](czh42778@163.com)  \n1Department of Thoracic Surgery, Huai’an Hospital of Huai’an City & Huai’an Cancer Hospital & The Affiliated Huai’an Hospital of Jiangsu College of Nursing, Huai’an, Jiangsu Province, China  \nprotein 4 (CTLA-4) in cancers including melanoma, lung cancers, and breast cancers [3–5]. However, despite these advancements, only a limited subgroup of patients is responsive to immune checkpoint blockade (ICB) therapy [6]. As a result, ongoing research aims to identify novel targets and strategies to improve the efficacy of immunotherapies and reverse resistance.  \nOne key reason for the limited response of cancer immunotherapy in solid cancers is the complicated and suppressive tumor immune microenvironment (TIME), which significantly hampers anti-tumor immune responses [7, 8]. The TIME is composed of various inhibitory cell types and factors, such as M2 macrophages, myeloid-derived suppressor cells (MDSCs), type 2 helper  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credi","cbCaigh4wcZ385fA","https://ap.wps.com/l/cbCaigh4wcZ385fA","pdf",4471455,12,"English","# Abstract\n# Introduction\n## Background: limits of immune checkpoint blockade\n## Role of the tumor immune microenvironment (TIME)\n## DKK3 functions in cancer and immune contexts","[{\"question\":\"Why is a new cancer immunotherapy target needed beyond immune checkpoint blockade?\",\"answer\":\"Only a limited subgroup of patients responds to ICB therapy. The suppressive tumor immune microenvironment (TIME) hampers anti-tumor immune responses, necessitating new targets.\"},{\"question\":\"What does the study report about DKK3 expression and patient outcomes?\",\"answer\":\"DKK3 expression is up-regulated in tumors from multiple cancer types. High DKK3 expression is associated with worse survival outcomes across different cancers.\"},{\"question\":\"How does DKK3 blockade affect anti-tumor immunity and therapy response?\",\"answer\":\"DKK3 blockade triggers effective anti-tumor effects in mouse models and improves survival. It remodels TIME by increasing infiltration of CD8+ T cells, IFN-γ+CD8+ T cells, and Th1 cells while decreasing M2 macrophages and MDSCs. Combined DKK3 and PD-1 blockade shows synergistic tumor control.\"}]","Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy | PDF",1790182298,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3604fc5872820db891d1ae40ee58880.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b386e61666615b1f09a926c56d1f110e.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02435e35cc0777fed78eadeeeec264c2.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e8e4c4ab9284989bdfe76512d27fa2a.webp",980,1306]